Orpheden Therapeutics

Orpheden Therapeutics
Northwestern University Invention #5
John Kuelper
jkuelper2014@kellogg.northwestern.edu

---

Orpheden is at an exciting point in the genesis of our company and of our novel Granulysin-based dendritic cell therapy (DCT) platform. After our success at the Breast Cancer Startup Challenge, our company is “thinking big” with our DCT platform, developing a dynamic business that will quickly bring our therapy to women’s and underserved cancers that are in dire need of it. We are actively implementing our plan and are gaining traction with strategic investors, business plan competitions, and clinicians and scientists who can help drive our company through the preclinical and clinical phases. It is a time of great growth for Orpheden, and we are excited as we continue to realize tangible outcomes from the theoretical possibilities of our business plan.